TY - JOUR
T1 - Ataxin-1 oligomers induce local spread of pathology and decreasing them by passive immunization slows spinocerebellar ataxia type 1 phenotypes
AU - Lasagna-Reeves, Cristian A.
AU - Rousseaux, Maxime W.C.
AU - Guerrero-Munoz, Marcos J.
AU - Vilanova-Velez, Luis
AU - Park, Jeehye
AU - See, Lauren
AU - Jafar-Nejad, Paymaan
AU - Richman, Ronald
AU - Orr, Harry T.
AU - Kayed, Rakez
AU - Zoghbi, Huda Y.
N1 - Publisher Copyright:
© Lasagna-Reeves et al.
PY - 2015/12/17
Y1 - 2015/12/17
N2 - Previously, we reported that ATXN1 oligomers are the primary drivers of toxicity in Spinocerebellar ataxia type 1 (SCA1; Lasagna-Reeves et al., 2015). Here we report that polyQ ATXN1 oligomers can propagate locally in vivo in mice predisposed to SCA1 following intracerebral oligomeric tissue inoculation. Our data also show that targeting these oligomers with passive immunotherapy leads to some improvement in motor coordination in SCA1 mice and to a modest increase in their life span. These findings provide evidence that oligomer propagation is regionally limited in SCA1 and that immunotherapy targeting extracellular oligomers can mildly modify disease phenotypes.
AB - Previously, we reported that ATXN1 oligomers are the primary drivers of toxicity in Spinocerebellar ataxia type 1 (SCA1; Lasagna-Reeves et al., 2015). Here we report that polyQ ATXN1 oligomers can propagate locally in vivo in mice predisposed to SCA1 following intracerebral oligomeric tissue inoculation. Our data also show that targeting these oligomers with passive immunotherapy leads to some improvement in motor coordination in SCA1 mice and to a modest increase in their life span. These findings provide evidence that oligomer propagation is regionally limited in SCA1 and that immunotherapy targeting extracellular oligomers can mildly modify disease phenotypes.
UR - http://www.scopus.com/inward/record.url?scp=84988638319&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988638319&partnerID=8YFLogxK
U2 - 10.7554/eLife.10891
DO - 10.7554/eLife.10891
M3 - Article
C2 - 26673892
AN - SCOPUS:84988638319
SN - 2050-084X
VL - 4
JO - eLife
JF - eLife
IS - DECEMBER2015
M1 - e10891
ER -